Rozanolixizumab is a medicine used to treat generalized myasthenia gravis, a condition that causes muscle weakness. It works by lowering the levels of the harmful antibodies that attack the connection between nerves and muscles. It's given as an injection under the skin in treatment cycles.
Every report comes from a Lived member, sent anonymously.
Have you tried Rystiggo (Rozanolixizumab) for Myasthenia Gravis?
Rozanolixizumab, sold as Rystiggo, is a prescription medicine for generalized myasthenia gravis in adults. Myasthenia gravis is an autoimmune disease in which the immune system makes antibodies that interfere with the signal from nerves to muscles, causing weakness that worsens with use and improves with rest. In the generalized form, that weakness reaches beyond the eyes and eyelids to muscles used for swallowing, speaking, breathing, or moving the arms and legs. Rystiggo is approved only for adults whose blood tests show one of two specific antibodies: antibodies against the acetylcholine receptor (AChR), the most common type, or against muscle-specific kinase (MuSK). It is not approved for people who test negative for both, for disease limited to the eye muscles, or for children. In its main study it was added to treatments people were already taking, such as medicines that strengthen nerve-to-muscle signaling, steroids or other immune-suppressing drugs, rather than replacing them.
The antibodies that cause myasthenia gravis belong to a family called IgG. Normally, IgG antibodies last a long time in the blood because a protein called the neonatal Fc receptor (FcRn) binds them and protects them from being broken down. Rozanolixizumab is a laboratory-made antibody that blocks FcRn. With that protection blocked, the body clears IgG antibodies faster, so their levels fall, including the harmful AChR or MuSK antibodies. Less of these antibodies at the nerve-muscle junction can mean less weakness. The effect is temporary: once a treatment cycle ends, antibody levels gradually rise again, which is why the medicine is given in repeated cycles. It lowers antibodies already in the blood but does not stop the immune system from making them.
Rystiggo is given as a slow infusion under the skin of the lower abdomen, using a small pump. In the United States it is prepared and given by a healthcare provider, and the dose is set by body weight. One treatment cycle is one infusion a week for 6 weeks. After that, the timing of the next cycle depends on how symptoms return rather than a fixed calendar, but a new cycle should not start sooner than 63 days (9 weeks) after the previous cycle began, because earlier restarts have not been studied for safety. In the long-term studies, people started about four cycles a year on average, though some needed as few as one and others up to seven. If a weekly dose is missed, it can be given up to 4 days late, and then the original schedule resumes. The care team will watch for allergic reactions during the infusion and for 15 minutes afterward.
Headache is the most common side effect, reported by about 44 in 100 people in the main study compared with 19 in 100 on placebo. A small number had severe headaches. Diarrhea, fever, nausea, infections and allergic-type reactions were also common, and some people notice redness or soreness where the infusion went in, usually within a few days. Allergic reactions, including rash and swelling of the face, lips or throat (angioedema), have occurred, sometimes days after an infusion. Contact the care team right away about any of these, and get emergency care if swelling makes it hard to breathe or swallow. A rare but serious reaction is aseptic meningitis, an inflammation of the lining around the brain and spinal cord that is not caused by an infection. It can look like a very severe headache with fever, stiff neck, nausea or vomiting, or sensitivity to light. Because headache is so common with this medicine, the combination with fever or stiff neck is the signal to contact the care team promptly rather than wait.
Lowering IgG antibodies also lowers part of the body's normal defense against germs, so infections are more likely. In studies, colds, COVID-19, urinary tract infections and cold sores were among the most frequent, and about 4 in 100 people had a serious infection. A cycle is usually postponed if someone has an active infection, and new signs of infection during treatment should be reported to the care team. Vaccines need some planning. Live vaccines are not recommended during treatment, and how well any vaccine works while IgG is lowered is not known. The care team usually reviews which vaccines are due before a new cycle starts. Because rozanolixizumab speeds the clearing of IgG, it can also clear medicines built from IgG, making them less effective. This includes immune globulin products and many monoclonal antibody medicines, including some used for other conditions. Anyone receiving these should make sure both prescribers know. There is little information about use during pregnancy. In animal studies, it caused pregnancy loss and weakened immune development in offspring. People who are pregnant, planning pregnancy or breastfeeding should discuss the risks and alternatives with their neurologist, and a registry collects outcomes for those exposed during pregnancy.
In the main study, people's scores on a standard scale of daily myasthenia symptoms (covering things like chewing, swallowing, speaking, breathing, eyelid drooping and limb strength, scored from 0 to 24) improved by about 3.4 points after one 6-week cycle, compared with 0.8 points on placebo. Some people improve within the first weeks of a cycle, but response varies, and not everyone improves meaningfully. Because the benefit fades as antibody levels recover, many people notice symptoms creeping back in the weeks or months after a cycle. The neurologist uses that pattern to decide when the next cycle is needed. This means treatment is ongoing rather than a cure, and follow-up visits focus on symptom control, side effects, infections and whether other myasthenia medicines can be adjusted. Rozanolixizumab is relatively new, so long-term information is still building, and it was not studied in enough people over 65 to know whether they respond differently.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Rystiggo (Rozanolixizumab), what you've noticed, or ask the community a question.